Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients
Sponsor: Wake Forest University Health Sciences
Summary
Pharmacogenomic (PGx) testing involves analyzing variants of genes associated with drug metabolism, transport and medication targets. PGx testing uses an individual's genetic factors, such as single nucleotide polymorphisms (SNPs), to personalize therapy or dose a selection of medications. PGx testing has traditionally been used to test single genes, but there are now platforms allowing a panel of genes to be tested at once. To date there has not been a comprehensive screening of pediatric oncology patients to determine the prevalence of genetic variants that may affect anticancer therapy and supportive care medications. This study would allow us to summarize the frequency of clinically relevant gene-drug interactions and actionable genetic polymorphisms in pediatric oncology patients.
Key Details
Gender
All
Age Range
Any - 26 Years
Study Type
INTERVENTIONAL
Enrollment
130
Start Date
2026-06
Completion Date
2028-07
Last Updated
2026-03-25
Healthy Volunteers
No
Conditions
Interventions
Pharmacogenomic Testing
Pharmacogenomic testing will be completed by the vendor. The vendor is certified under CLIA-88 and accredited by the College of American Pathologists as qualified to perform high-complexity testing. Genomic DNA extracted from the swab will be analyzed by PCR using Thermo Fisher TaqMan® and/or LGC Biosearch BHQ® probe-based methods to interrogate the variant locations listed in (See Appendix II). Twenty-seven genes are evaluated and reported.
Locations (1)
Levine Childrens Hospital Pediatric Cancer and Blood Disorders
Charlotte, North Carolina, United States